Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Edesa Biotech, Inc. (EDSA)
USD6.87
+0.13 (+1.93%)
CA NASDAQ Healthcare Biotechnology
Address
100 Spy Court L3R 5H6
Markham, ON, CA
Markham, ON, CA
CEO
Pardeep Nijhawan
Website
edesabiotech.com
IPO
2010-06-21
CIK 1540159 ISIN CA27966L3065
Description
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.87
+0.13 (+1.93%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
523.8K
Beta
1.05
Float Shares
7.64M
Free Float %
91.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.13% | -15.50% | +179.89% | +1,332.35% | +734.86% | +928.87% | +619.70% | +137.18% | -65.27% | -98.40% | -97.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
6.87
DCF (Unlevered)
1.83
-73.3%
DCF (Levered)
1.90
-72.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
23.21
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+34.2% ★ Q1'26: -66.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q1'26: -3,960.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%— Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-432.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+77.5% Q1'26: +55.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2025 actual |
Sep 2026 1 EPS Ana. |
Sep 2027 2 Rev. Ana. 1 EPS Ana. |
Sep 2028 2 Rev. Ana. 2 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
758.7K
est: 695.0K (+9.2%)
|
1.27M
est: 1.15M (+10.4%)
|
228.3K
est: 605.0K (-62.3%)
|
211.8K
est: 211.8K (+0.0%)
|
410.9K
est: 939.1K (-56.2%)
|
328.8K
est: 255.0K (+28.9%)
|
—
|
—
— – —
|
19.00M
19.00M – 19.00M
|
49.00M
49.00M – 49.00M
+157.9% YoY
|
9.80M
9.80M – 9.80M
-80.0% YoY
|
30.30M
30.30M – 30.30M
+209.2% YoY
|
| EBITDA |
-2.65M
|
-4.87M
|
-4.85M
|
-4.85M
|
-2.83M
|
-6.35M
|
-7.07M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-4.34M
|
-4.91M
|
-5.03M
|
-5.04M
|
-2.83M
|
-6.40M
|
-7.18M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-2.84M
est: -4.77M (+40.4%)
|
-5.03M
est: -135.90M (+96.3%)
|
-5.03M
est: -112.06M (+95.5%)
|
-5.04M
est: -419.62M (+98.8%)
|
-2.72M
est: -250.34M (+98.9%)
|
-6.36M
est: -29.21M (+78.2%)
|
-7.19M
est: -6.61M (-8.6%)
|
-9.28M
-9.28M – -9.28M
-40.3% YoY
|
-9.88M
-9.88M – -9.88M
-6.4% YoY
|
-7.44M
-11.75M – -3.12M
+24.7% YoY
|
-11.58M
-11.58M – -11.58M
-55.7% YoY
|
-7.72M
-7.72M – -7.72M
+33.3% YoY
|
| SGA |
3.23M
|
3.32M
|
2.94M
|
2.76M
|
2.05M
|
3.38M
|
4.24M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-15.01
est: -0.84 (-1,686.9%)
|
-23.92
est: -23.94 (+0.1%)
|
-218.72
est: -19.74 (-1,008.0%)
|
-10.54
est: -73.92 (+85.7%)
|
-4.15
est: -44.10 (+90.6%)
|
-5.18
est: -5.15 (-0.7%)
|
-1.27
est: -1.17 (-8.5%)
|
-1.64
-1.64 – -1.64
-39.7% YoY
|
-1.74
-1.74 – -1.74
-6.4% YoY
|
-1.31
-2.07 – -0.55
+24.7% YoY
|
-2.04
-2.04 – -2.04
-55.7% YoY
|
-1.36
-1.36 – -1.36
+33.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-7.62M
OE per share TTM
-1.01
Owner's Yield
-6.32%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
68.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
1.70M
Insider transactions (90d)
1
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pardeep Nijhawan | 4.42M | 22.10% | 773.9K | 3.64M | 773.9K | 3.64M | IN | Canadian | 2022-11-08 | ↗ |
| 2 | Pardeep Nijhawan Medicine Professional Corporation | 2.59M | 13.20% | — | 2.59M | — | 2.59M | CO | — | 2022-11-08 | ↗ |
| 3 | Benjamin Rovinski | 2.00M | 22.60% | — | 2.00M | — | 10.00 | IN | Canadian | 2020-01-16 | ↗ |
| 4 | Daniel Hetu | 2.00M | 22.60% | — | 2.00M | — | 10.00 | IN | Canadian | 2020-01-16 | ↗ |
| 5 | Gerald Brunk | 2.00M | 22.60% | — | 2.00M | — | 10.00 | IN | States | 2020-01-16 | ↗ |
| 6 | Lumira Capital GP, L.P. | 2.00M | 22.60% | — | 2.00M | — | 10.00 | PN | Canada | 2020-01-16 | ↗ |
| 7 | Lumira Capital Investment Management Inc. | 2.00M | 22.60% | — | 2.00M | — | 10.00 | CO | Canada | 2020-01-16 | ↗ |
| 8 | Lumira GP Holdings Co. | 2.00M | 22.60% | — | 2.00M | — | 10.00 | CO | Scotia, Canada | 2020-01-16 | ↗ |
| 9 | Lumira GP Inc. | 2.00M | 22.60% | — | 2.00M | — | 10.00 | CO | Canada | 2020-01-16 | ↗ |
| 10 | Peter van der Velden | 2.00M | 22.60% | — | 2.00M | — | 10.00 | IN | Canadian | 2020-01-16 | ↗ |
| 11 | Vasco Larcina | 2.00M | 22.60% | — | 2.00M | — | 10.00 | IN | Canadian | 2020-01-16 | ↗ |
| 12 | Lumira Capital II, L.P. | 1.83M | 20.70% | — | 1.83M | — | 10.00 | PN | Canada | 2020-01-16 | ↗ |
| 13 | Adam Morgan | 1.78M | 8.78% | — | 1.78M | — | 1.78M | IN | Delaware | 2023-01-06 | ↗ |
| 14 | Balaji Venkataraman | 1.78M | 8.78% | — | 1.78M | — | 1.78M | IN | Delaware | 2023-01-06 | ↗ |
| 15 | Velan Capital Holdings LLC | 1.78M | 8.78% | — | 1.78M | — | 1.78M | OO | Delaware | 2023-01-06 | ↗ |
| 16 | Velan Capital Investment Management LP | 1.78M | 8.78% | — | 1.78M | — | 1.78M | PN | Delaware | 2023-01-06 | ↗ |
| 17 | Velan Capital Management LLC | 1.78M | 8.78% | — | 1.78M | — | 1.78M | OO | Delaware | 2023-01-06 | ↗ |
| 18 | Velan Capital Partners LP | 1.78M | 8.78% | — | 1.78M | — | 1.78M | PN | Delaware | 2023-01-06 | ↗ |
| 19 | 10379085 Canada Inc. | 690.8K | 7.80% | — | 690.8K | — | 10.00 | CO | Canada | 2020-01-23 | ↗ |
| 20 | David Goodman | 690.8K | 7.80% | — | 690.8K | — | 10.00 | IN | Canada | 2020-01-23 | ↗ |
| 21 | Gregory Orleski | 690.8K | 7.80% | — | 690.8K | — | 10.00 | IN | Canada | 2020-01-23 | ↗ |
| 22 | Jean-Guy Goulet | 690.8K | 7.80% | — | 690.8K | — | 10.00 | IN | Canada | 2020-01-23 | ↗ |
| 23 | Morris Goodman | 690.8K | 7.80% | — | 690.8K | — | 10.00 | IN | Canada | 2020-01-23 | ↗ |
| 24 | PCRI Inc. | 690.8K | 7.80% | — | 690.8K | — | 10.00 | CO | Canada | 2020-01-23 | ↗ |
| 25 | Sonia Girolamo | 690.8K | 7.80% | — | 690.8K | — | 10.00 | IN | Canada | 2020-01-23 | ↗ |
| 26 | The New Nijhawan Family Trust 2015 | 456.5K | 2.30% | — | 456.5K | — | 456.5K | OO | — | 2022-11-08 | ↗ |
| 27 | 1968160 Ontario Inc. | 371.7K | 1.90% | — | 371.7K | — | 371.7K | CO | — | 2022-11-08 | ↗ |
| 28 | The Digestive Health Clinic Inc. | 224.1K | 1.20% | — | 224.1K | — | 224.1K | CO | — | 2022-11-08 | ↗ |
| 29 | Lumira Capital II (International), L.P. | 169.5K | 1.90% | — | 169.5K | — | 10.00 | PN | Canada | 2020-01-16 | ↗ |
| 30 | Daniel B. Asher | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-02-11 | ↗ |
| 31 | Intracoastal Capital LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2020-02-11 | ↗ |
| 32 | Mitchell P. Kopin | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-7 vs prev Q
New positions
9
Closed positions
16
Increased
10
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 687.5K +— (+0.0%) | 976.3K -721.9K (-42.5%) | 9.74% -0.051 pp | 0.57% -1.029 pp | USD2.44 -41.8% | 4 qtrs — |
| 2 | RUBRIC CAPITAL MANAGEMENT LP | 687.5K +— (+0.0%) | 976.3K -721.9K (-42.5%) | 9.74% -0.051 pp | 0.01% -0.008 pp | USD2.44 -41.8% | 4 qtrs — |
| 3 | STONEPINE CAPITAL MANAGEMENT, LLC | 687.5K +— (+0.0%) | 976.3K -721.9K (-42.5%) | 9.74% -0.051 pp | 0.71% -0.668 pp | USD2.47 -42.5% | 4 qtrs — |
| 4 | NANTAHALA CAPITAL MANAGEMENT, LLC | 625.0K +— (+0.0%) | 887.5K -656.3K (-42.5%) | 8.85% -0.046 pp | 0.03% -0.024 pp | USD2.44 -41.8% | 4 qtrs — |
| 5 | DRW SECURITIES, LLC | 134.2K +134.2K (+100.0%) | 190.6K +190.6K (+100.0%) | 1.68% +1.684 pp | 0.01% +0.005 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 6 | CITADEL ADVISORS LLC | 53.6K +39.6K (+282.2%) | 77.8K +43.5K (+127.1%) | 0.67% +0.473 pp | 0.00% +0.000 pp | USD1.51 -6.0% | 5 qtrs — |
| 7 | DIADEMA PARTNERS LP | 54.0K +54.0K (+100.0%) | 76.7K +76.7K (+100.0%) | 0.68% +0.678 pp | 0.01% +0.013 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 46.5K +1.3K (+2.9%) | 67.5K -42.9K (-38.9%) | 0.58% -0.060 pp | 0.00% +0.000 pp | USD3.28 -56.7% | 9 qtrs — |
| 9 | VANGUARD GROUP INC | 37.6K -7.9K (-17.4%) | 54.5K -56.6K (-50.9%) | 0.47% -0.177 pp | 0.00% +0.000 pp | USD3.20 -55.6% | 9 qtrs — |
| 10 | STATE STREET CORP | 18.7K +18.7K (+100.0%) | 27.1K +27.1K (+100.0%) | 0.23% +0.234 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 11 | PERSISTENT ASSET PARTNERS LTD | 12.3K +12.3K (+100.0%) | 17.5K +17.5K (+100.0%) | 0.15% +0.155 pp | 0.01% +0.008 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 12 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.6K +1.3K (+99.7%) | 3.6K +468.0 (+14.8%) | 0.03% +0.014 pp | 0.00% +0.000 pp | USD1.85 -23.2% | 9 qtrs — |
| 13 | MORGAN STANLEY | 2.3K +2.3K (+100.0%) | 3.3K +3.3K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 9 qtrs — |
| 14 | ROYAL BANK OF CANADA | 1.7K -157.0 (-8.6%) | 2.0K -2.0K (-50.0%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD4.17 -65.9% | 9 qtrs — |
| 15 | UBS GROUP AG | 1.4K -457.0 (-25.1%) | 1.9K -2.6K (-57.0%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD2.30 -38.3% | 9 qtrs — |
| 16 | TD WATERHOUSE CANADA INC. | 142.00 +— (+0.0%) | 200.00 -162.0 (-44.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.56 -68.9% | 9 qtrs — |
| 17 | GLOBAL RETIREMENT PARTNERS, LLC | 86.00 +61.0 (+244.0%) | 122.00 +60.0 (+96.8%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.58 -10.1% | 3 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 52.00 +1.0 (+2.0%) | 74.00 -52.0 (-41.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.81 -49.5% | 7 qtrs — |
| 19 | DANSKE BANK A/S | 1.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -64.5% | 6 qtrs — |
| 20 | LRI INVESTMENTS, LLC | 1.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -29.0% | 3 qtrs — |
| 21 | DOGWOOD WEALTH MANAGEMENT LLC | 1.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +42.0% | 5 qtrs — |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -14.6K (-100.0%) | — -35.6K (-100.0%) | 0.00% -0.208 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 23 | FIFTH THIRD BANCORP | — -100.0 (-100.0%) | — -247.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 24 | COMMONWEALTH EQUITY SERVICES, LLC | — -37.5K (-100.0%) | — -93.0K (-100.0%) | 0.00% -0.535 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 25 | RENAISSANCE TECHNOLOGIES LLC | — -25.0K (-100.0%) | — -61.8K (-100.0%) | 0.00% -0.356 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 26 | CITIGROUP INC | — -2.0K (-100.0%) | — -4.9K (-100.0%) | 0.00% -0.029 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 27 | BARCLAYS PLC | — -6.0 (-100.0%) | — -14.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 569.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
3.7K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+3,737
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 1,159 | 0.00 | — | 632,550 | D | ↗ |
| 2026-04-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 2,578 | 0.00 | — | 631,391 | D | ↗ |
| 2026-03-05 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 10,000 | 3.90 | 39.0K | 402,702 | I | ↗ |
| 2026-03-04 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 10,000 | 4.26 | 42.6K | 392,702 | I | ↗ |
| 2026-03-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 10,000 | 3.63 | 36.3K | 382,702 | I | ↗ |
| 2026-03-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 2.00 | 4.0K | 627,813 | D | ↗ |
| 2026-02-27 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 30,000 | 2.22 | 66.7K | 371,702 | I | ↗ |
| 2026-02-26 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 20,571 | 1.58 | 32.5K | 615,797 | D | ↗ |
| 2026-02-26 | Brooks Michael J | Officer | P-Purchase | A | Common Shares | 2,000 | 1.57 | 3.1K | 226,870 | D | ↗ |
| 2026-02-19 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 82,236 | 0.00 | — | 595,226 | D | ↗ |
| 2026-02-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 11,168 | 0.00 | — | 512,990 | D | ↗ |
| 2026-01-05 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 10,444 | 0.00 | — | 501,822 | D | ↗ |
| 2025-12-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 8,766 | 0.00 | — | 491,378 | D | ↗ |
| 2025-11-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 6,968 | 0.00 | — | 482,612 | D | ↗ |
| 2025-10-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 5,908 | 0.00 | — | 475,644 | D | ↗ |
| 2025-09-11 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 5,981 | 0.00 | — | 469,736 | D | ↗ |
| 2025-08-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 6,802 | 0.00 | — | 463,755 | D | ↗ |
| 2025-07-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 7,186 | 0.00 | — | 456,953 | D | ↗ |
| 2025-06-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 7,644 | 0.00 | — | 449,767 | D | ↗ |
| 2025-05-29 | Weiler Peter J. | Officer | A-Award | A | Common Shares | 65,000 | 0.00 | — | 65,000 | D | ↗ |
| 2025-05-29 | Sistilli Carlo | Director | A-Award | A | Common Shares | 20,001 | 0.00 | — | 30,417 | D | ↗ |
| 2025-05-29 | Olson Charles V | Director | A-Award | A | Common Shares | 11,000 | 0.00 | — | 11,000 | D | ↗ |
| 2025-05-29 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 263,200 | 0.00 | — | 442,123 | D | ↗ |
| 2025-05-29 | Marshall Patrick | Director | A-Award | A | Common Shares | 11,000 | 0.00 | — | 52,666 | D | ↗ |
| 2025-05-29 | MacDonald Sean Arthur | Director | A-Award | A | Common Shares | 20,001 | 0.00 | — | 22,054 | D | ↗ |
| 2025-05-29 | Liu Da David | Director | A-Award | A | Common Shares | 5,501 | 0.00 | — | 5,501 | D | ↗ |
| 2025-05-29 | Chypyha Joan | Director | A-Award | A | Common Shares | 11,000 | 0.00 | — | 11,029 | D | ↗ |
| 2025-05-29 | Brooks Michael J | Officer | A-Award | A | Common Shares | 207,201 | 0.00 | — | 224,870 | D | ↗ |
| 2025-05-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 6,392 | 0.00 | — | 178,923 | D | ↗ |
| 2025-05-01 | Weiler Peter J. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 5,784 | 0.00 | — | 172,531 | D | ↗ |
| 2025-03-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 6,339 | 0.00 | — | 166,747 | D | ↗ |
| 2025-02-12 | Sistilli Carlo | Director | A-Award | A | Common Shares | 10,416 | 1.92 | 20.0K | 10,416 | D | ↗ |
| 2025-02-12 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Series B-1 Convertible Preferred Shares | 100 | 0.02 | 2.00 | 100 | D | ↗ |
| 2025-02-12 | Marshall Patrick | Director | A-Award | A | Common Shares | 41,666 | 1.92 | 80.0K | 41,666 | D | ↗ |
| 2025-02-12 | Liu Da David | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-02-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 8,264 | 0.00 | — | 160,408 | D | ↗ |
| 2025-01-06 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 8,476 | 0.00 | — | 152,144 | D | ↗ |
| 2024-12-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 6,420 | 0.00 | — | 143,668 | D | ↗ |
| 2024-11-12 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 4,630 | 0.00 | — | 137,248 | D | ↗ |
| 2024-10-30 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Series A-1 Convertible Preferred Shares | 150 | 3.45 | 516.75 | 150 | I | ↗ |
| 2024-10-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 3,300 | 0.00 | — | 132,618 | D | ↗ |
| 2024-09-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 3,055 | 0.00 | — | 129,318 | — | ↗ |
| 2024-08-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 3,317 | 0.00 | — | 126,263 | — | ↗ |
| 2024-07-02 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 4,015 | 0.00 | — | 122,946 | — | ↗ |
| 2024-06-03 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 4,785 | 0.00 | — | 118,931 | — | ↗ |
| 2024-05-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Share | 3,083 | 0.00 | — | 114,146 | — | ↗ |
| 2024-04-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 3,253 | 0.00 | — | 111,063 | — | ↗ |
| 2024-03-25 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 5,000 | 4.00 | 20.0K | 341,702 | — | ↗ |
| 2024-03-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 2,765 | 0.00 | — | 107,810 | — | ↗ |
| 2024-02-01 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 2,978 | 0.00 | — | 105,045 | — | ↗ |
| 2024-01-08 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 2,908 | 0.00 | — | 102,067 | — | ↗ |
| 2023-08-04 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 99,300 | 0.00 | — | 694,112 | — | ↗ |
| 2023-08-04 | Lemieux Stephen | Officer | A-Award | A | Common Shares | 17,400 | 0.00 | — | 17,400 | — | ↗ |
| 2023-08-04 | Brooks Michael J | Officer | A-Award | A | Common Shares | 93,200 | 0.00 | — | 123,680 | — | ↗ |
| 2023-07-20 | Sistilli Carlo | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | Olson Charles V | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | OAKES FRANK R. | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Share Option (right to buy) | 120,000 | 0.83 | 99.3K | 120,000 | — | ↗ |
| 2023-07-20 | Marshall Patrick | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | MacDonald Sean Arthur | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | Lemieux Stephen | Officer | A-Award | A | Share Option (right to buy) | 75,000 | 0.83 | 62.1K | 75,000 | — | ↗ |
| 2023-07-20 | Chypyha Joan | Director | A-Award | A | Share Option (right to buy) | 20,000 | 0.83 | 16.6K | 20,000 | — | ↗ |
| 2023-07-20 | Brooks Michael J | Officer | A-Award | A | Share Option (right to buy) | 80,000 | 0.83 | 66.2K | 80,000 | — | ↗ |
| 2023-07-15 | Lemieux Stephen | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-23 | Olson Charles V | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-23 | Marshall Patrick | Director | — | I | Common Shares | 0 | 0.00 | — | 3,254 | — | ↗ |
| 2023-05-23 | Chypyha Joan | Director | — | D | Common Shares | 0 | 0.00 | — | 200 | — | ↗ |
| 2023-01-10 | van der Velden Peter | Director | S-Sale | D | Common share | 139,450 | 2.63 | 367.4K | 1,625,133 | — | ↗ |
| 2023-01-09 | van der Velden Peter | Director | S-Sale | D | Common share | 12,284 | 2.66 | 32.7K | 163,170 | — | ↗ |
| 2022-11-02 | Nijhawan Pardeep | Director / Officer | A-Award | A | Common Shares | 228,262 | 1.13 | 256.8K | 2,356,914 | — | ↗ |
| 2022-11-02 | NIFFENEGGER KATHI | Director / Officer | A-Award | A | Common Shares | 8,888 | 1.13 | 10.0K | 10,715 | — | ↗ |
| 2022-11-02 | Brooks Michael J | Director | A-Award | A | Common Shares | 4,239 | 1.13 | 4.8K | 30,480 | — | ↗ |
| 2022-06-30 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 20,000 | 1.60 | 32.1K | 594,812 | — | ↗ |
| 2022-06-30 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 20,000 | 1.60 | 32.1K | 594,812 | — | ↗ |
| 2022-06-29 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 3,000 | 1.49 | 4.5K | 26,241 | — | ↗ |
| 2022-06-16 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 3,000 | 1.61 | 4.8K | 23,241 | — | ↗ |
| 2022-05-27 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 5,000 | 1.92 | 9.6K | 574,812 | — | ↗ |
| 2022-05-27 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 5,000 | 1.92 | 9.6K | 574,812 | — | ↗ |
| 2022-05-25 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 3,500 | 1.74 | 6.1K | 20,241 | — | ↗ |
| 2022-05-24 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 1.80 | 3.6K | 569,812 | — | ↗ |
| 2022-05-24 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 1.80 | 3.6K | 569,812 | — | ↗ |
| 2022-03-31 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 2.99 | 6.0K | 567,812 | — | ↗ |
| 2022-03-31 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 2.99 | 6.0K | 567,812 | — | ↗ |
| 2022-03-30 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 3.05 | 6.1K | 565,812 | — | ↗ |
| 2022-03-30 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 3.05 | 6.1K | 565,812 | — | ↗ |
| 2022-03-29 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 3.02 | 6.0K | 563,812 | — | ↗ |
| 2022-03-29 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 3.02 | 6.0K | 563,812 | — | ↗ |
| 2022-03-28 | Chao Jennifer M | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-18 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 3.85 | 7.7K | 561,812 | — | ↗ |
| 2022-03-18 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 3.85 | 7.7K | 561,812 | — | ↗ |
| 2022-03-17 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 397 | 3.25 | 1.3K | 558,209 | — | ↗ |
| 2022-03-17 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 1,603 | 3.26 | 5.2K | 559,812 | — | ↗ |
| 2022-03-15 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 2,000 | 2.80 | 5.6K | 557,812 | — | ↗ |
| 2022-03-15 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 2.80 | 5.6K | 557,812 | — | ↗ |
| 2022-03-14 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 1,250 | 2.79 | 3.5K | 16,741 | — | ↗ |
| 2022-03-11 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 5,000 | 3.06 | 15.3K | 555,812 | — | ↗ |
| 2022-03-11 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 5,000 | 3.06 | 15.3K | 555,812 | — | ↗ |
| 2022-03-10 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 1,000 | 3.22 | 3.2K | 15,491 | — | ↗ |
| 2022-03-09 | Pardeep Nijhawan Medicine Professional Corp | Director / Officer | P-Purchase | A | Common Shares | 1,500 | 3.05 | 4.6K | 548,812 | — | ↗ |
| 2022-03-09 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 1,500 | 3.05 | 4.6K | 548,812 | — | ↗ |
| 2022-03-08 | Brooks Michael J | Director | P-Purchase | A | Common Shares | 1,250 | 2.90 | 3.6K | 14,491 | — | ↗ |
| 2022-02-28 | Sistilli Carlo | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 3.71 | 40.8K | 11,000 | — | ↗ |
| 2022-02-28 | Pay Paul William | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 3.71 | 40.8K | 11,000 | — | ↗ |
| 2022-02-28 | OAKES FRANK R. | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 3.71 | 40.8K | 11,000 | — | ↗ |
| 2022-02-28 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 49,000 | 3.71 | 181.8K | 49,000 | — | ↗ |
| 2022-02-28 | NIFFENEGGER KATHI | Officer | A-Award | A | Stock Option (right to buy) | 43,500 | 3.71 | 161.4K | 43,500 | — | ↗ |
| 2022-02-28 | MacDonald Sean Arthur | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 3.71 | 40.8K | 11,000 | — | ↗ |
| 2022-02-28 | JOHNSON LORIN K | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 3.71 | 40.8K | 11,000 | — | ↗ |
| 2022-02-28 | Brooks Michael J | Officer | A-Award | A | Stock Option (right to buy) | 43,500 | 3.71 | 161.4K | 43,500 | — | ↗ |
| 2021-04-22 | van der Velden Peter | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | Sistilli Carlo | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | Pay Paul William | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | OAKES FRANK R. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 120,000 | 5.45 | 654.0K | 120,000 | — | ↗ |
| 2021-04-22 | NIFFENEGGER KATHI | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 5.45 | 436.0K | 80,000 | — | ↗ |
| 2021-04-22 | MacDonald Sean Arthur | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | JOHNSON LORIN K | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.45 | 109.0K | 20,000 | — | ↗ |
| 2021-04-22 | Brooks Michael J | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 5.45 | 436.0K | 80,000 | — | ↗ |
| 2021-03-25 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 3,000 | 5.25 | 15.8K | 545,312 | — | ↗ |
| 2021-03-25 | Brooks Michael J | Officer | P-Purchase | A | Common Shares | 3,500 | 5.19 | 18.2K | 13,241 | — | ↗ |
| 2021-03-24 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 5,000 | 5.16 | 25.8K | 542,312 | — | ↗ |
| 2021-03-24 | Brooks Michael J | Officer | P-Purchase | A | Common stock | 4,500 | 5.08 | 22.9K | 9,741 | — | ↗ |
| 2021-02-18 | OAKES FRANK R. | Director | S-Sale | D | Common Shares | 6,165 | 7.25 | 44.7K | 0 | — | ↗ |
| 2020-11-09 | JOHNSON LORIN K | Director | X-InTheMoney | A | Common Shares | 4,262 | 4.00 | 17.0K | 12,786 | — | ↗ |
| 2020-11-06 | Pay Paul William | Director | X-InTheMoney | A | Common Shares | 1,218 | 4.00 | 4.9K | 3,654 | — | ↗ |
| 2020-11-06 | NIFFENEGGER KATHI | Officer | X-InTheMoney | A | Common Shares | 609 | 4.00 | 2.4K | 1,827 | — | ↗ |
| 2020-11-06 | Brooks Michael J | Officer | X-InTheMoney | A | Common Shares | 914 | 4.00 | 3.7K | 5,241 | — | ↗ |
| 2020-11-05 | Sistilli Carlo | Director | X-InTheMoney | D | Common Share Warrants (Right to Buy) | 1,218 | 4.00 | 4.9K | 0 | — | ↗ |
| 2020-11-05 | Nijhawan Pardeep | Director / Officer / 10% Owner | X-InTheMoney | D | Common share warrants (Right to buy) | 4,628 | 4.00 | 18.5K | 0 | — | ↗ |
| 2020-11-02 | van der Velden Peter | Director / 10% Owner | X-InTheMoney | A | Common Shares | 64,362 | 4.00 | 257.4K | 1,897,428 | — | ↗ |
| 2020-10-13 | van der Velden Peter | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | Sistilli Carlo | Director | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | Pay Paul William | Director | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | OAKES FRANK R. | Director | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Stock option (right to buy) | 60,000 | 7.44 | 446.4K | 60,000 | — | ↗ |
| 2020-10-13 | NIFFENEGGER KATHI | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 7.44 | 372.0K | 50,000 | — | ↗ |
| 2020-10-13 | MacDonald Sean Arthur | Director | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | JOHNSON LORIN K | Director | A-Award | A | Stock option (right to buy) | 20,000 | 7.44 | 148.8K | 20,000 | — | ↗ |
| 2020-10-13 | Brooks Michael J | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 7.44 | 372.0K | 50,000 | — | ↗ |
| 2020-10-06 | OAKES FRANK R. | Director | X-InTheMoney | A | Common Shares | 609 | 4.00 | 2.4K | 1,827 | — | ↗ |
| 2020-09-17 | Nijhawan Pardeep | Director / Officer / 10% Owner | J-Other | A | Common Shares | 371,727 | 0.00 | — | 371,727 | — | ↗ |
| 2020-05-27 | Brooks Michael J | Officer | P-Purchase | A | Common Shares | 1,500 | 3.00 | 4.5K | 3,327 | — | ↗ |
| 2020-05-26 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 3,000 | 2.98 | 8.9K | 2,124,024 | — | ↗ |
| 2020-03-29 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 2,000 | 5.23 | 10.5K | 547,312 | — | ↗ |
| 2020-03-17 | Nijhawan Pardeep | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 1,000 | 1.90 | 1.9K | 2,121,024 | — | ↗ |
| 2020-02-12 | van der Velden Peter | Director / 10% Owner | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | Sistilli Carlo | Director | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | Pay Paul William | Director | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | OAKES FRANK R. | Director | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | NIFFENEGGER KATHI | Officer | A-Award | A | Share Option (Right to Buy) | 88,699 | 3.16 | 280.3K | 88,699 | — | ↗ |
| 2020-02-12 | MacDonald Sean Arthur | Director | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | JOHNSON LORIN K | Director | A-Award | A | Share Option (Right to Buy) | 11,389 | 3.16 | 36.0K | 11,389 | — | ↗ |
| 2020-02-12 | Brooks Michael J | Officer | A-Award | A | Share Option (Right to Buy) | 68,988 | 3.16 | 218.0K | 68,988 | — | ↗ |
| 2020-01-08 | van der Velden Peter | Director / 10% Owner | P-Purchase | A | Common Share Warrants (Right to Buy) | 96,542 | 4.80 | 463.4K | 96,542 | — | ↗ |
| 2020-01-08 | Sistilli Carlo | Director | P-Purchase | A | Common Share Warrants (Right to Buy) | 1,827 | 4.80 | 8.8K | 1,827 | — | ↗ |
| 2020-01-08 | Pay Paul William | Director | A-Award | A | Common Shares | 2,436 | 4.11 | 10.0K | 2,436 | — | ↗ |
| 2020-01-08 | OAKES FRANK R. | Director | A-Award | A | Common Share Warrants (Right to Buy) | 609 | 4.00 | 2.4K | 609 | — | ↗ |
| 2020-01-08 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Common Shares | 9,255 | 4.11 | 38.0K | 2,116,024 | — | ↗ |
| 2020-01-08 | NIFFENEGGER KATHI | Officer | A-Award | A | Common Share Warrants (Right to Buy) | 609 | 4.00 | 2.4K | 609 | — | ↗ |
| 2020-01-08 | JOHNSON LORIN K | Director | P-Purchase | A | Common Shares | 8,524 | 4.11 | 35.0K | 8,524 | — | ↗ |
| 2020-01-08 | Brooks Michael J | Officer | P-Purchase | A | Common Shares | 1,827 | 4.11 | 7.5K | 1,827 | — | ↗ |
| 2019-09-11 | OAKES FRANK R. | Director | S-Sale | D | Common Shares | 1,809 | 5.72 | 10.3K | 6,165 | — | ↗ |
| 2019-07-26 | van der Velden Peter | Director / 10% Owner | A-Award | A | Common Shares | 8,600 | 0.00 | — | 157,599 | — | ↗ |
| 2019-07-26 | Pay Paul William | Director | A-Award | A | Stock Option (right to buy) | 1,820 | 2.16 | 3.9K | 32,399 | — | ↗ |
| 2019-07-26 | Nijhawan Pardeep | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 91 | 2.16 | 196.56 | 1,620 | — | ↗ |
| 2019-07-26 | MacDonald Sean Arthur | Director | A-Award | A | Common Shares | 786 | 0.00 | — | 14,369 | — | ↗ |
| 2019-07-26 | Brooks Michael J | Officer | A-Award | A | Stock Option (right to buy) | 91 | 2.16 | 196.56 | 1,620 | — | ↗ |
| 2019-06-07 | van der Velden Peter | Director / 10% Owner | A-Award | A | Common Shares | 1,611,338 | 0.00 | — | 1,611,338 | — | ↗ |
| 2019-06-07 | Sistilli Carlo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-07 | Pay Paul William | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-07 | Nijhawan Pardeep | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-07 | MacDonald Sean Arthur | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-07 | JOHNSON LORIN K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-06-07 | Brooks Michael J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-12 | SAMPAT MAYANK D. | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-12 | Olson Charles V | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-12 | HILL DAVID LOUIS | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-12 | Chun Paul | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-12 | Che Tessie M | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-12 | Aghib Deborah F. | Director | A-Award | A | Share Option (Right to Buy) | 357 | 1.25 | 446.25 | 357 | — | ↗ |
| 2019-03-06 | OAKES FRANK R. | Director / Officer | S-Sale | D | Common Shares, without par value | 4,000 | 1.25 | 5.0K | 47,924 | — | ↗ |
| 2018-10-12 | OAKES FRANK R. | Director / Officer | S-Sale | D | Common Shares, without par value | 3,000 | 1.31 | 3.9K | 51,924 | — | ↗ |
| 2018-10-12 | MORSE DANIEL E. | — | S-Sale | D | Common Shares, without par value | 7,047 | 1.31 | 9.3K | 20,741 | — | ↗ |
| 2018-03-29 | MORSE DANIEL E. | Director | S-Sale | D | Common Shares, without par value | 4,366 | 0.81 | 3.5K | 0 | — | ↗ |
| 2018-03-12 | SAMPAT MAYANK D. | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-12 | Olson Charles V | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-12 | OAKES FRANK R. | Director / Officer | A-Award | A | Share Option (Right to Buy) | 40,000 | 0.84 | 33.6K | 40,000 | — | ↗ |
| 2018-03-12 | NIFFENEGGER KATHI | Officer | A-Award | A | Share Option (Right to Buy) | 35,000 | 0.84 | 29.4K | 35,000 | — | ↗ |
| 2018-03-12 | MORSE DANIEL E. | Director | S-Sale | D | Common shares, without par value | 3,500 | 0.80 | 2.8K | 4,366 | — | ↗ |
| 2018-03-12 | HILL DAVID LOUIS | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-12 | Chun Paul | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-12 | Che Tessie M | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-12 | BAXTER GREGORY T. | Officer | A-Award | A | Share Option (Right To Buy) | 30,000 | 0.84 | 25.2K | 30,000 | — | ↗ |
| 2018-03-12 | Aghib Deborah F. | Director | A-Award | A | Share Option (Right to Buy) | 2,500 | 0.84 | 2.1K | 2,500 | — | ↗ |
| 2018-03-09 | MORSE DANIEL E. | Director | S-Sale | D | Common shares, without par value | 7,000 | 0.81 | 5.6K | 7,866 | — | ↗ |
| 2018-02-28 | MORSE DANIEL E. | Director | S-Sale | D | Common shares, without par value | 7,000 | 0.79 | 5.5K | 14,866 | — | ↗ |
| 2018-02-26 | MORSE DANIEL E. | Director | S-Sale | D | Common shares, without par value | 7,000 | 0.79 | 5.5K | 21,866 | — | ↗ |
| 2018-02-22 | MORSE DANIEL E. | Director | S-Sale | D | Common Shares, without par value | 7,800 | 0.78 | 6.1K | 28,866 | — | ↗ |
| 2018-01-23 | Aghib Deborah F. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
8.35M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 357.7K | 93.7K | 522.9K | — | — | 32.4K | 1.01M | 51.94% | ↗ |
| 2 | 2025 | Michael Brooks, PhD President | 335.3K | 87.9K | 411.7K | — | — | 27.0K | 861.9K | 47.76% | ↗ |
| 3 | 2025 | Stephen Lemieux, CPA Former Chief Financial Of icer | 192.5K | 86.5K | 111.9K | — | — | 32.1K | 422.9K | 26.45% | ↗ |
| 4 | 2025 | Peter Weiler Chief Financial Officer | 125.0K | — | 129.1K | — | — | 10.6K | 264.7K | 48.79% | ↗ |
| 5 | 2024 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 357.7K | 72.4K | — | — | — | 34.6K | 464.7K | 0.00% | ↗ |
| 6 | 2024 | Michael Brooks, PhD President | 335.3K | 67.9K | — | — | — | 25.7K | 429.0K | 0.00% | ↗ |
| 7 | 2024 | Stephen Lemieux, CPA Chief Financial Officer | 330.0K | 14.1K | — | — | — | 24.0K | 368.1K | 0.00% | ↗ |
| 8 | 2024 | Stephen Lemieux, CPA Former Chief Financial Of icer | 330.0K | 14.1K | — | — | — | 24.0K | 368.1K | 0.00% | ↗ |
| 9 | 2023 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 341.4K | 99.3K | — | 74.2K | — | 34.6K | 549.6K | 13.51% | ↗ |
| 10 | 2023 | Michael Brooks, PhD President | 320.1K | 93.2K | — | 49.5K | — | 26.1K | 488.8K | 10.13% | ↗ |
| 11 | 2023 | Kathi Niffenegger, CPA Former Chief Financial Officer | 253.4K | 102.1K | — | 49.5K | — | 48.4K | 453.4K | 10.92% | ↗ |
| 12 | 2023 | Stephen Lemieux, CPA Chief Financial Officer | 82.5K | — | 13.9K | 46.4K | — | 13.1K | 155.9K | 38.68% | ↗ |
| 13 | 2022 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 325.9K | 89.6K | — | 123.2K | — | 63.1K | 601.7K | 20.47% | ↗ |
| 14 | 2022 | Michael Brooks, PhD President | 305.5K | 96.0K | — | 109.3K | — | 41.9K | 552.7K | 19.78% | ↗ |
| 15 | 2022 | Kathi Niffenegger, CPA Chief Financial Officer | 295.1K | 87.0K | — | 109.3K | — | 50.5K | 542.0K | 20.17% | ↗ |
| 16 | 2022 | Kathi Niffenegger, CPA Former Chief Financial Officer | 295.1K | 87.0K | — | 109.3K | — | 50.5K | 542.0K | 20.17% | ↗ |
| 17 | 2021 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 315.0K | 120.0K | — | 820.5K | — | 63.8K | 1.32M | 62.19% | ↗ |
| 18 | 2021 | Michael Brooks, PhD President | 293.8K | 110.0K | — | 605.9K | — | 42.3K | 1.05M | 57.59% | ↗ |
| 19 | 2021 | Kathi Niffenegger, CPA Chief Financial Officer | 305.0K | 100.0K | — | 605.9K | — | 30.9K | 1.04M | 58.16% | ↗ |
| 20 | 2020 | Michael Brooks, PhD President | 275.0K | 51.3K | — | 166.7K | — | 36.2K | 529.2K | 31.49% | ↗ |
| 21 | 2020 | Kathi Niffenegger, CPA Chief Financial Officer | 234.1K | 31.4K | — | 214.3K | — | 25.6K | 505.3K | 42.40% | ↗ |
| 22 | 2020 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 300.0K | 56.0K | — | — | — | 55.2K | 411.2K | 0.00% | ↗ |
| 23 | 2019 | Michael Brooks, PhD President | 158.1K | 37.2K | — | — | — | 11.9K | 207.3K | 0.00% | ↗ |
| 24 | 2019 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 105.5K | — | — | — | — | 24.6K | 130.0K | 0.00% | ↗ |
| 25 | 2019 | Kathi Niffenegger, CPA Chief Financial Officer | 63.6K | 53.8K | — | — | — | 5.0K | 122.4K | 0.00% | ↗ |
| 26 | 2018 | Michael Brooks, PhD President | 170.4K | 51.7K | — | 1.6K | — | 7.3K | 231.0K | 0.69% | ↗ |
| 27 | 2018 | Pardeep Nijhawan, MD Director, Chief Executive Officer and Corporate Secretary | 27.1K | — | — | 1.6K | — | 32.4K | 61.1K | 2.61% | ↗ |
| 28 | 2017 | Frank R. Oakes President, Chief Executive Officer and Chairman of the Board of Directors | 257.1K | 25.0K | 297.0K | — | — | 23.7K | 602.7K | 49.27% | ↗ |
| 29 | 2017 | Kathi Niffenegger, CPA Chief Financial Officer and Corporate Secretary | 202.6K | 20.0K | — | 19.7K | — | 18.5K | 260.8K | 7.57% | ↗ |
| 30 | 2017 | Gregory T. Baxter, Ph.D. Executive Vice President of Corporate Development | 157.4K | 500.00 | — | 15.6K | — | 18.4K | 191.9K | 8.13% | ↗ |
| 31 | 2016 | Frank R. Oakes, President, Chief Executive Officer and Chairman of our Board of Directors | 250.1K | 120.0K | — | — | — | 59.7K | 429.8K | 0.00% | ↗ |
| 32 | 2016 | Frank R. Oakes President, Chief Executive Officer and Chairman of the Board of Directors | 250.1K | 120.0K | — | — | — | 59.7K | 429.8K | 0.00% | ↗ |
| 33 | 2016 | Mark McPartland Vice President of Corporate Development and Communications | 215.0K | 46.4K | — | 122.3K | — | 13.0K | 396.6K | 30.83% | ↗ |
| 34 | 2016 | Kathi Niffenegger, CPA Chief Financial Officer and Corporate Secretary | 196.6K | 47.3K | — | 61.1K | — | 19.0K | 324.0K | 18.88% | ↗ |
| 35 | 2016 | Kathi Niffenegger, CPA, Chief Financial Officer and Corporate Secretary | 196.6K | 47.3K | — | 61.1K | — | 19.0K | 324.0K | 18.87% | ↗ |
| 36 | 2016 | Catherine Brisson, Ph.D., Chief Operating Officer | 173.6K | 47.7K | — | 61.1K | — | 12.9K | 295.3K | 20.70% | ↗ |
| 37 | 2016 | Gregory T. Baxter, Ph.D. Executive Vice President of Corporate Development | — | — | — | — | — | 11.8K | 11.8K | 0.00% | ↗ |
| 38 | 2015 | Frank R. Oakes, President, CEO and Director | 240.0K | 90.0K | — | — | — | 25.6K | 355.6K | 0.00% | ↗ |
| 39 | 2015 | Frank R. Oakes, President, Chief Executive Officer and Chairman of our Board of Directors | 240.0K | 90.0K | — | — | — | 25.6K | 355.6K | 0.00% | ↗ |
| 40 | 2015 | Kathi Niffenegger, CPA Chief Financial Officer and Corporate Secretary | 189.0K | 27.0K | — | 106.3K | — | 17.3K | 339.6K | 31.30% | ↗ |
| 41 | 2015 | Kathi Niffenegger, CPA, Chief Financial Officer and Corporate Secretary | 189.0K | 27.0K | — | 106.3K | — | 17.3K | 339.6K | 31.30% | ↗ |
| 42 | 2015 | Catherine Brisson, Ph.D., Chief Operating Officer | 190.8K | 18.0K | — | — | — | 14.0K | 222.8K | 0.00% | ↗ |
| 43 | 2015 | Mark A. McPartland Vice-president of Corporate Development and Communications | 185.4K | 5.4K | — | — | — | 7.2K | 198.0K | 0.00% | ↗ |
| 44 | 2015 | Mark McPartland Vice President of Corporate Development and Communications | 185.4K | 5.4K | — | — | — | 7.2K | 198.0K | 0.00% | ↗ |
| 45 | 2014 | Frank R. Oakes, President, CEO and Director | 222.3K | 180.0K | — | — | — | 21.4K | 423.7K | 0.00% | ↗ |
| 46 | 2014 | Frank R. Oakes, President, CEO and Director | 222.3K | 180.0K | — | — | — | 21.4K | 423.7K | 0.00% | ↗ |
| 47 | 2014 | Frank R. Oakes, President, Chief Executive Officer and Chairman of our Board of Directors | 222.3K | 180.0K | — | — | — | 21.4K | 423.7K | 0.00% | ↗ |
| 48 | 2014 | Herbert Chow, Ph.D., Chief Technology Officer | 178.3K | — | — | 162.9K | — | 18.1K | 359.3K | 45.33% | ↗ |
| 49 | 2014 | Kathi Niffenegger, CPA, Chief Financial Officer and Corporate Secretary | 175.0K | — | — | 162.9K | — | 15.1K | 353.0K | 46.15% | ↗ |
| 50 | 2014 | Kathi Niffenegger, CPA Chief Financial Officer and Corporate Secretary | 175.0K | — | — | 162.9K | — | 15.1K | 353.0K | 46.15% | ↗ |
| 51 | 2014 | Kathi Niffenegger, Chief Financial Officer and Corporate Secretary | 175.0K | — | — | 162.9K | — | 15.1K | 353.0K | 46.15% | ↗ |
| 52 | 2014 | Catherine Brisson, Ph.D., Chief Operating Officer | 178.3K | — | — | 162.9K | — | 11.4K | 352.6K | 46.20% | ↗ |
| 53 | 2014 | Catherine Brisson, Ph.D., Chief Operating Officer | 178.3K | — | — | 162.9K | — | 11.4K | 352.6K | 46.20% | ↗ |
| 54 | 2014 | Mark McPartland Vice President of Corporate Development and Communications | 139.8K | — | — | 162.9K | — | 282.00 | 302.9K | 53.77% | ↗ |
| 55 | 2014 | Mark A. McPartland Vice-president of Corporate Development and Communications | 139.8K | — | — | 162.9K | — | 282.00 | 302.9K | 53.77% | ↗ |
| 56 | 2013 | Herbert Chow, Ph.D., Chief Technology Officer | 155.8K | — | — | 74.9K | — | 13.2K | 243.9K | 30.69% | ↗ |
| 57 | 2013 | Catherine Brisson, Ph.D., Chief Operating Officer | 155.8K | — | — | 48.1K | — | 8.6K | 212.6K | 22.63% | ↗ |
| 58 | 2013 | Catherine Brisson, Ph.D., Chief Operating Officer | 155.8K | — | — | 48.1K | — | 8.6K | 212.6K | 22.63% | ↗ |
| 59 | 2013 | Kathi Niffenegger, CPA Chief Financial Officer and Corporate Secretary | 137.5K | — | — | 55.2K | — | 11.0K | 203.7K | 27.10% | ↗ |
| 60 | 2013 | Kathi Niffenegger, Chief Financial Officer and Corporate Secretary | 137.5K | — | — | 55.2K | — | 11.0K | 203.7K | 27.10% | ↗ |
| 61 | 2013 | Frank R. Oakes, President, CEO and Director | 33.3K | — | — | — | — | 19.6K | 52.9K | 0.00% | ↗ |
| 62 | 2013 | Frank R. Oakes, President, CEO and Director | 33.3K | — | — | — | — | 19.6K | 52.9K | 0.00% | ↗ |
| 63 | 2012 | Kathi Niffenegger, Chief Financial Officer and Corporate Secretary | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pardeep Nijhawan FRCPC | Chief Executive Officer, Company Secretary & Director | 483.8K | — |
| Michael J. Brooks | President | 450.2K | — |
| Peter John Weiler | Chief Financial Officer | 310.6K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EDSA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
